Prognostic impacts of serum uric acid levels in patients with chronic heart failure: insights from the CHART-2 study.


Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
04 2021
Historique:
revised: 29 03 2020
received: 24 10 2019
accepted: 27 04 2020
pubmed: 31 12 2020
medline: 2 7 2021
entrez: 30 12 2020
Statut: ppublish

Résumé

Prognostic impacts of serum uric acid (UA) levels in patients with chronic heart failure (CHF) remain inconclusive, especially for the whole range of serum UA levels. In the Chronic Heart Failure Registry and Analysis in the Tohoku District-2 (CHART-2) study, we enrolled 4652 consecutive patients with CHF and classified them into four groups based on baseline serum UA levels by the Classification and Regression Tree: G1 (<3.8 mg/dL, N = 313), G2 (3.8-7.1 mg/dL, N = 3070), G3 (7.2-9.2 mg/dL, N = 1018), and G4 (>9.2 mg/dL, N = 251). Mean age was 71 ± 12, 69 ± 12, 68 ± 13, and 69 ± 15 years in G1, G2, G3, and G4, respectively (P < 0.001). During the median follow-up of 6.3 years, in G1, G2, G3, and G4, 111 (35%), 905 (29%), 370 (36%), and 139 (55%) patients died and 79 (25%), 729 (24%), 300 (29%), and 115 (46%) experienced heart failure hospitalization, respectively (both P < 0.001). G1 was characterized by a significantly high prevalence of women as compared with G2, G3, and G4 (59%, 32%, 24%, and 23%, respectively). Serum creatinine levels (0.8 ± 0.4, 0.9 ± 0.4, 1.2 ± 0.6, and 1.4 ± 0.8 mg/dL, respectively), prevalence of atrial fibrillation (34%, 39%, 45%, and 50%, respectively), and diuretics use (36%, 45%, 67%, and 89%, respectively) increased from G1, G2, G3 to G4 (all P < 0.001), while left ventricular ejection fraction decreased from G1, G2, G3 to G4 (59 ± 15, 58 ± 15, 54 ± 15, and 52 ± 17%, respectively, P < 0.001). Multivariable Cox proportional hazards models showed that, as compared with G2, both G1 and G4 had increased incidence of all-cause death [adjusted hazard ratio (aHR) 1.34, 95% confidence interval (CI) 1.08-1.67, P = 0.009; aHR 1.28, 95% CI 1.02-1.61, P = 0.037, respectively] and heart failure admission (aHR 1.39, 95% CI 1.09-1.78, P = 0.008 and aHR 1.35, 95% CI, 1.06-1.71, P = 0.014, respectively). This U-shaped relationship was evident in the elderly patients. Furthermore, abnormal transitions to either higher or lower levels of serum UA from G2 were associated with increased mortality (aHR 1.29, 95% CI 1.06-1.57, P = 0.012; aHR 1.57, 95% CI 1.12-2.20, P = 0.009). These results demonstrate that serum UA levels have the U-shaped prognostic effects and abnormal transitions to either higher or lower levels are associated with poor prognosis in the elderly patients with CHF.

Identifiants

pubmed: 33377627
doi: 10.1002/ehf2.12765
pmc: PMC8006606
doi:

Substances chimiques

Uric Acid 268B43MJ25

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1027-1038

Informations de copyright

© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Nephrol Dial Transplant. 2004 Feb;19(2):457-62
pubmed: 14736974
J Am Heart Assoc. 2019 Dec 3;8(23):e013130
pubmed: 31752638
Arthritis Care Res (Hoboken). 2011 Jan;63(1):102-10
pubmed: 20824805
Am J Hum Genet. 2008 Dec;83(6):744-51
pubmed: 19026395
Clin Nutr ESPEN. 2017 Oct;21:51-58
pubmed: 30014869
Lancet. 1999 Nov 6;354(9190):1578
pubmed: 10560670
Int J Cardiol. 2011 Sep 1;151(2):143-7
pubmed: 20542341
Arthritis Care Res (Hoboken). 2010 Feb;62(2):170-80
pubmed: 20191515
Nature. 2002 May 23;417(6887):447-52
pubmed: 12024214
Clin Rheumatol. 2008 Apr;27(4):483-9
pubmed: 17874170
Sci Rep. 2016 Jan 27;6:19520
pubmed: 26814153
Congest Heart Fail. 2012 May-Jun;18(3):179-82
pubmed: 22587748
N Engl J Med. 1971 Dec 23;285(26):1441-6
pubmed: 5122894
Eur J Heart Fail. 2017 Oct;19(10):1258-1269
pubmed: 28370829
N Engl J Med. 2008 Oct 23;359(17):1811-21
pubmed: 18946066
Circulation. 2012 Jul 3;126(1):65-75
pubmed: 22615345
Int J Endocrinol. 2011;2011:604715
pubmed: 22114591
Eur J Heart Fail. 2014 Jan;16(1):15-24
pubmed: 23933579
Circ J. 2011;75(4):823-33
pubmed: 21436596
Hypertension. 2000 Dec;36(6):1072-8
pubmed: 11116127
ESC Heart Fail. 2021 Apr;8(2):1027-1038
pubmed: 33377627
Circ J. 2016 May 25;80(6):1396-403
pubmed: 27170200
Eur Heart J. 2011 Mar;32(6):712-20
pubmed: 21199831
Proc Natl Acad Sci U S A. 1981 Nov;78(11):6858-62
pubmed: 6947260
Congest Heart Fail. 2011 Jan-Feb;17(1):25-30
pubmed: 21272224
Metabolism. 2018 Jun;83:205-215
pubmed: 29477817
Am J Kidney Dis. 1998 Dec;32(6):917-33
pubmed: 9856507
Eur J Heart Fail. 2015 Sep;17(9):884-92
pubmed: 26222508
Ann Intern Med. 1999 Jul 6;131(1):7-13
pubmed: 10391820
Arthritis Rheumatol. 2018 Jul;70(7):1122-1132
pubmed: 29694719
Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1018-29
pubmed: 22132951
J Card Fail. 2010 Nov;16(11):880-7
pubmed: 21055652
Circ J. 2015;79(11):2396-407
pubmed: 26356834
Eur J Intern Med. 2009 Jan;20(1):74-9
pubmed: 19237097
BMC Cardiovasc Disord. 2019 Jan 5;19(1):4
pubmed: 30611196
Acta Diabetol. 2007 Sep;44(3):99-105
pubmed: 17721747
Int J Cardiol. 2016 Jun 15;213:4-7
pubmed: 26341316
Med Hypotheses. 2008;70(3):578-81
pubmed: 17689199
Ann Rheum Dis. 2006 Aug;65(8):981-2
pubmed: 16837492
QJM. 2011 Dec;104(12):1015-24
pubmed: 21908382
PLoS One. 2014 Jun 24;9(6):e100801
pubmed: 24959886
Circ J. 2015;79(5):1125-32
pubmed: 25739858
Am J Epidemiol. 1988 Feb;127(2):321-36
pubmed: 3337086
J Clin Endocrinol Metab. 2015 Nov;100(11):4198-207
pubmed: 26308292
Heart Fail Rev. 2013 Mar;18(2):177-86
pubmed: 22584465
J Intern Med. 2009 Dec;266(6):558-70
pubmed: 19563390
J Am Coll Cardiol. 2009 Apr 14;53(15):e1-e90
pubmed: 19358937
Eur J Clin Invest. 1997 Jun;27(6):484-90
pubmed: 9229228
J Am Heart Assoc. 2018 Feb 10;7(4):
pubmed: 29440009

Auteurs

Takahide Fujihashi (T)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.

Yasuhiko Sakata (Y)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.
Big Data Medicine Center, Tohoku University, Sendai, Japan.

Kotaro Nochioka (K)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.
Big Data Medicine Center, Tohoku University, Sendai, Japan.

Masanobu Miura (M)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.

Ruri Abe (R)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.

Shintaro Kasahara (S)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.

Masayuki Sato (M)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.

Hajime Aoyanagi (H)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.

Shinsuke Yamanaka (S)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.

Hideka Hayashi (H)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.

Takashi Shiroto (T)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.

Koichiro Sugimura (K)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.

Jun Takahashi (J)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.

Satoshi Miyata (S)

Department of Evidence-Based Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Hiroaki Shimokawa (H)

Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan.
Big Data Medicine Center, Tohoku University, Sendai, Japan.
Department of Evidence-Based Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH